Kirkstall wins grant to develop brain cancer 'tumour on a chip' model for glioblastoma research

Kirkstall Limited, a subsidiary of Imaging Biometrics Ltd, received funding from BBSRC and NC3Rs to develop a microfluidic 'tumour on a chip' model for glioblastoma, the most aggressive adult brain cancer. This model will simulate the blood-brain barrier and tumour environment using human-derived cells to improve drug testing accuracy, overcoming limitations of animal models. The project, in collaboration with Nottingham Trent University, aims to enhance glioblastoma treatment development by enabling better study of drug penetration and tumour growth. Imaging Biometrics CEO highlighted the synergy with their MRI analysis software, potentially transforming glioblastoma research.